Feldan Therapeutics, a biopharmaceutical company that develops therapeutics based on its proprietary intracellular delivery platform, announced today it was awarded funding by the Cystic Fibrosis Foundation to pursue the development of the Feldan Shuttle technology as a pulmonary delivery agent for cystic fibrosis (CF).

Feldan is a biopharmaceutical company that specializes in the development of treatments based on the intracellular delivery of therapeutics. Feldan designed a proprietary, peptide-based technology that enables safe and efficient delivery of various compounds inside cells. The Shuttle technology unlocks the development of a new generation of therapies by giving access to intracellular components beyond the reach of existing drugs. Feldan's pipeline focuses on diseases affecting lungs and skin.
For more information: www.feldan.com
SOURCE Feldan Therapeutics

Feldan Therapeutics Awarded Funding By Cystic Fibrosis Foundation

Description

Company Information

Feldan Therapeutics Awarded Funding By Cystic Fibrosis Foundation

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Company Information